Latest news with #32ndEuropeanCongressonObesity
Mid East Info
13-05-2025
- Health
- Mid East Info
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss - Middle East Business News and Information
Participants achieved an average weight loss of 20.2% with tirzepatide vs. 13.7% with semaglutide In key secondary endpoints, tirzepatide was superior to semaglutide across all weight reduction targets and waist circumference reduction Dubai, United Arab Emirates, May, 2025 – A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ≥10% weight loss 81.6% 60.5% Achieved ≥15% weight loss 64.6% 40.1% Achieved ≥20% weight loss 48.4% 27.3% Achieved ≥25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. About SURMOUNT-5: SURMOUNT-5 (NCT05822830) was a 72-week, multi-center, randomized, open-label, phase 3b trial evaluating the efficacy and safety of tirzepatide compared with semaglutide in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea (OSA) or cardiovascular disease, who did not have diabetes. Participants in both treatment groups received counseling on a reduced-calorie diet and increased physical activity. The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg). With tirzepatide, 89.3% received at least one dose of the 15 mg dose and with semaglutide 92.8% received at least one dose of the 2.4 mg dose. The primary objective of the study was to demonstrate tirzepatide's superiority in percent change from baseline in body weight at 72 weeks compared to semaglutide's. About tirzepatide: Tirzepatide is a once-weekly dual GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing. About Lilly: Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
Web Release
12-05-2025
- Health
- Web Release
Tirzepatide Outperforms Semaglutide by 47% in Weight Loss
By Editor_wr On May 12, 2025 A clinical study has presented detailed findings from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2% compared to 13.7% with semaglutide at 72 weeks using treatment-regimen estimand,1 a 47% greater relative weight loss. Participants using tirzepatide lost an average of 50.3 lbs (22.8 kg) and participants on semaglutide lost an average of 33.1 lbs (15.0 kg).2 In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6% of participants treated with tirzepatide achieving at least 15.0% weight loss compared to 40.1% on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5. 'The SURMOUNT-5 head-to-head results demonstrated tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' Primary and Key Secondary Endpoints: Tirzepatide Semaglutide Primary Endpoint Avg % weight loss -20.2% -13.7% Key Secondary Endpoints Achieved ?10% weight loss 81.6% 60.5% Achieved ?15% weight loss 64.6% 40.1% Achieved ?20% weight loss 48.4% 27.3% Achieved ?25% weight loss 31.6% 16.1% Waist circumference reduction -18.4 cm -13.0 cm 'In the SURMOUNT-5 trial, tirzepatide demonstrated a significantly higher magnitude of weight reduction compared to semaglutide across all comparisons,' said Leonard Glass, MD, FACE, senior vice president, global medical affairs, Lilly. 'These data confirm tirzepatide as a leading treatment option for people living with obesity and equip healthcare providers with critical insights to make well-informed treatment decisions as part of a comprehensive obesity care plan.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1% of participants taking tirzepatide discontinued treatment due to adverse events, compared to 8.0% of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide Outperforms Semaglutide by 47% in Weight Loss Comments are closed.
India Gazette
12-05-2025
- Health
- India Gazette
Weight loss drug Mounjaro shown more effective than Wegovy, claims Pharma company
New Delhi [India], May 12 (ANI): Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes, according to a press statement. According to Eli Lilly, participants reduced 20.2 per cent weight with tirzepatide in comparison to 13.7 per cent with semaglutide across the trials. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. The statement added, 'For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2 per cent compared to 13.7 per cent with semaglutide at 72 weeks using treatment-regimen estimand,1 47 per cent greater relative weight loss. Participants using tirzepatide lost an average of 22.8 kg and participants on semaglutide lost an average of 15.0 kg.2.' In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6 per cent of participants treated with tirzepatide achieving at least 15.0 per cent weight loss compared to 40.1 per cent on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before,' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5,' as per the statement. 'The SURMOUNT-5 head-to-head results demonstrated that tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' 'Obesity is a chronic disease that requires comprehensive management, and Lilly is committed to supporting people with obesity and enhancing the standard of care in obesity management in India', said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). 'The results from the SURMOUNT 5 trial provide robust evidence supporting Mounjaro (tirzepatide) as an effective option for obesity management in India.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1 per cent of participants taking tirzepatide discontinued treatment due to adverse events, compared to eight per cent of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide is a weight loss drug for adults with obesity or with overweight who also have weight-related medical problems, as Zepbound in the US and Mounjaro in some countries outside of the US Tirzepatide is also commercialised as Mounjaro for adults with type 2 diabetes in the US and in some countries outside of the US. Semaglutide is a drug used as Wegovy for people living with obesity or for overweight adults who also have weight-related medical problems and Ozempic for people with type 2 diabetes. (ANI)
09-05-2025
- Health
Weight-loss meds may give people more control over drinking, study shows
Popular obesity and diabetes drugs called GLP-1 medications may have added benefits, with a new study finding they helped heavy drinkers cut alcohol consumption by nearly 70%. The study, published Friday during the 32nd European Congress on Obesity in Spain, also found these GLP-1 drugs were more effective than a drug called nalmefene, which is approved in Europe explicitly to help people cut back on alcohol. For the study, researchers followed 262 adults who were prescribed GLP-1 medications like semaglutide or liraglutide to help with weight loss. The researchers also tracked changes in alcohol use to explore a possible added benefit. Heavy drinkers -- those consuming 11 or more units of alcohol per week, roughly equal to six or more standard drinks like beers or glasses of wine -- saw the biggest drops in consumption. Notably, no participants reported drinking more after starting the medication. And it seemed to work equally well for men and women. Patients also lost about 17 pounds on average over four months. People who drank less tended to lose a little more weight, the researchers noted, possibly because they were cutting back on alcohol's empty calories. "The significance of this has to be taken into context of what's available to treat alcohol use disorder," Dr. Maurice O'Farrell, lead author of the study and founder of the Medication Weight Loss Clinic in Dublin, Ireland, told ABC News. "The real advantage that this medication has is compliance, and what this medication does is it gives people a degree of control, it gives the concrete guardrails, and that is something that is completely unique." Scientists have been studying other possible health benefits of GLP-1s besides diabetes management and weight loss for this class of medication, which includes drugs like Ozempic and Wegovy, in the wake of their booming popularity. Prior studies and anecdotal reports from patients have hinted that these medications may help cut cravings for alcohol and other addictive substances. One possible explanation is that they act on parts of the brain that control reward and satisfaction. According to the study, GLP-1 drugs may affect brain chemicals tied to pleasure and fullness, though more research is needed to fully understand the exact mechanism. "They attenuate dopamine release in reward pathways, and these pathways are common to food satisfaction but also to the pleasure people get from alcohol," O'Farrell said. "They drink more slowly and also the gastric emptying is slowed -- that means the absorption of alcohol is slower, so it is less pleasurable." Because this study took place in a real-world clinical setting -- not a controlled lab -- it may better reflect how people actually drink alcohol in everyday life. But the study did have a few limitations. There was no control group for comparison and researchers relied on people to report their own drinking habits, which they don't always remember accurately. About a third of the participants didn't complete the study, which makes the results less certain. If these results are confirmed in larger studies, O'Farrell said he thinks they could offer a new way to help people cut back on alcohol, especially those who haven't had success with current treatments.
Yahoo
09-05-2025
- Health
- Yahoo
Weight-loss meds may give people more control over drinking, study shows
Popular obesity and diabetes drugs called GLP-1 medications may have added benefits, with a new study finding they helped heavy drinkers cut alcohol consumption by nearly 70%. The study, published Friday during the 32nd European Congress on Obesity in Spain, also found these GLP-1 drugs were more effective than a drug called nalmefene, which is approved in Europe explicitly to help people cut back on alcohol. For the study, researchers followed 262 adults who were prescribed GLP-1 medications like semaglutide or liraglutide to help with weight loss. The researchers also tracked changes in alcohol use to explore a possible added benefit. Heavy drinkers -- those consuming 11 or more units of alcohol per week, roughly equal to six or more standard drinks like beers or glasses of wine -- saw the biggest drops in consumption. Notably, no participants reported drinking more after starting the medication. And it seemed to work equally well for men and women. Patients also lost about 17 pounds on average over four months. People who drank less tended to lose a little more weight, the researchers noted, possibly because they were cutting back on alcohol's empty calories. "The significance of this has to be taken into context of what's available to treat alcohol use disorder," Dr. Maurice O'Farrell, lead author of the study and founder of the Medication Weight Loss Clinic in Dublin, Ireland, told ABC News. "The real advantage that this medication has is compliance, and what this medication does is it gives people a degree of control, it gives the concrete guardrails, and that is something that is completely unique." Women turn to weight loss drugs in menopause: What to know about the benefits and risks Scientists have been studying other possible health benefits of GLP-1s besides diabetes management and weight loss for this class of medication, which includes drugs like Ozempic and Wegovy, in the wake of their booming popularity. Prior studies and anecdotal reports from patients have hinted that these medications may help cut cravings for alcohol and other addictive substances. One possible explanation is that they act on parts of the brain that control reward and satisfaction. According to the study, GLP-1 drugs may affect brain chemicals tied to pleasure and fullness, though more research is needed to fully understand the exact mechanism. "They attenuate dopamine release in reward pathways, and these pathways are common to food satisfaction but also to the pleasure people get from alcohol," O'Farrell said. "They drink more slowly and also the gastric emptying is slowed -- that means the absorption of alcohol is slower, so it is less pleasurable." Because this study took place in a real-world clinical setting -- not a controlled lab -- it may better reflect how people actually drink alcohol in everyday life. Woman says Ozempic helped her stop drinking: Here's what the research says about how it may work But the study did have a few limitations. There was no control group for comparison and researchers relied on people to report their own drinking habits, which they don't always remember accurately. About a third of the participants didn't complete the study, which makes the results less certain. If these results are confirmed in larger studies, O'Farrell said he thinks they could offer a new way to help people cut back on alcohol, especially those who haven't had success with current treatments. Dr. Keerthana Pakanati is a Cardiovascular Disease Fellow at Virginia Mason Franciscan Health and a member of the ABC News Medical Unit. Weight-loss meds may give people more control over drinking, study shows originally appeared on
